Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 2/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.40 |
| ▸ | CHRNB1 | P11230 | 3/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.40 |
| ▸ | CHRNB3 | Q05901 | 3/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.40 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12411148 | 0.88 | HRH4 (0.45) | NMT1CHRNB4CHRNA3 | |
| SCHEMBL449178 | 0.78 | NMT1 (0.51) | NMT1 | |
| SCHEMBL12501242 | 0.77 | CHRNB1 (0.51) | CHRNB4CHRNA3CHRNB1CHRNB2CHRNB3 | |
| SCHEMBL12090228 | 0.70 | HRH3 (0.53) | CHRNB4CHRNA3CHRNB1CHRNB2CHRNB3 | |
| SCHEMBL28112390 | 0.69 | PDE6D (0.39) | — | |
| SCHEMBL12500192 | 0.69 | CXCR4 (0.40) | CHRNB2CHRNA4 | |
| SCHEMBL12996146 | 0.68 | SYK (0.36) | — | |
| SCHEMBL15360083 | 0.68 | MKNK1 (0.46) | — | |
| Hydrochloric Acid SCHEMBL27429700 | 0.67 | ADRA2A (0.47) | CHRNB4CHRNA3 | |
| SCHEMBL24467086 | 0.66 | NOS1 (0.45) | NMT1CHRNB4CHRNA3CHRNB1CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166146-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SUNOVION PHARMACEUTICALS INC. (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166146-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | PAICS, ITPA, DPYD | NMT1 2261/4885CHRNB4 1451/4885CHRNA3 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.